Whitehall seeking ibuprofen monograph status, citing 13 years of OTC marketing data.
WHITEHALL SEEKING IBUPROFEN 200 MG MONOGRAPH STATUS in a citizen petition submitted to FDA Nov. 25. Whitehall-Robins Healthcare, a division of American Home Products, is asking FDA to include ibuprofen, which the company markets as Advil, in the internal analgesic, antipyretic and antirheumatic OTC drug products tentative final monograph as a single analgesic-antipyretic active ingredient labeled: "For the temporary relief of minor aches and pains associated with a cold, sore throat, headache, toothache, muscular aches, backache, premenstrual and menstrual cramps (dysmenorrhea) and for the minor pain from arthritis, and to reduce fever."
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
No mass exodus was seen from stand-alone prescription drug plans to Medicare Advantage drug plans between 2024 and 2025, according to one actuary.
PhRMA questioned whether proof-of-concept studies are needed before an INTERACT meeting and said a draft guidance describing the timing of definitive toxicology studies creates confusion.
Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.